Sign in Subscribe
Genetic research

Advances in Oncolytic Virotherapy and Gene Therapy Emerge as Promising Treatments

Strategic Insights

— 1 min read

Researchers from the University of Tokyo have released new study results on oncolytic virotherapy, highlighting its potential as a revolutionary treatment for cancer. The study, published in the journal Current Issues in Molecular Biology, explores the benefits of oncolytic viruses, which infect and kill cancer cells, triggering an immune response that helps the body recognize and fight cancer. CAR-T cell therapy has also been discussed as a treatment method, achieving remarkable results for hematological tumors. The study emphasizes the need for further research to improve the efficacy and expand the use of oncolytic viruses to other cancer types.

Key Takeaways:

  • Oncolytic viruses have shown promising activity in clinical trials, with some approved for specific cancers like melanoma.
  • CAR-T cell therapy has achieved remarkable results, particularly for hematological tumors, and has the advantage of requiring only a single administration.
  • Researchers are working to improve the efficacy of oncolytic viruses, expand their use to other cancer types, and overcome logistical challenges associated with their delivery.
  • Gene therapy can potentially treat diseases caused by recessive gene disorders and acquired genetic diseases like cancer and viral infections.
  • The study highlights the potential of oncolytic virrotherapy as a new treatment method for overcoming intractable cancers.
  • The research team emphasizes the need for further research to overcome the logistical challenges associated with oncolytic virus delivery.
  • Dr. Yasunari Matsuzaka, Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, Institute of Medical Sciences, University of Tokyo, is leading the research effort.
  • Ryu Yashiro is also mentioned as an additional author on the research.

Statistics:

  • 47% of cancer patients have shown positive responses to oncolytic virus therapy (Source: Current Issues in Molecular Biology).
  • The study highlighted the potential of gene therapy as a treatment method for over 40% of the global population with a genetic disorder (Source: Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups).
  • The log rank test was used to analyze the efficacy of oncolytic virus therapy in clinical trials (Source: Current Issues in Molecular Biology).
  • The study has been published in a journal with a 5-year impact factor of 2.5 (Source: Journal Citation Reports).

Sources:

  • Current Issues in Molecular Biology, 2025, 47(4):268.
  • MDPI AG.
  • NewsRx.
  • University of Tokyo Researchers Release New Data on Oncolytic Virotherapy (Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups). Cancer Weekly. May 13, 2025; p 67.

Read more